CIRESI, Alessandro
 Distribuzione geografica
Continente #
NA - Nord America 7.110
EU - Europa 2.897
AS - Asia 869
SA - Sud America 11
AF - Africa 7
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 5
Totale 10.906
Nazione #
US - Stati Uniti d'America 7.096
IT - Italia 1.258
CN - Cina 693
FI - Finlandia 419
IE - Irlanda 240
UA - Ucraina 240
DE - Germania 200
GB - Regno Unito 139
SE - Svezia 87
RU - Federazione Russa 80
FR - Francia 76
KR - Corea 52
TR - Turchia 42
RO - Romania 35
IN - India 32
BE - Belgio 30
PL - Polonia 19
NL - Olanda 16
ES - Italia 14
CH - Svizzera 10
AT - Austria 9
HK - Hong Kong 7
CA - Canada 6
GR - Grecia 6
IR - Iran 6
MX - Messico 6
AU - Australia 5
EG - Egitto 5
LB - Libano 5
TW - Taiwan 5
BG - Bulgaria 4
DK - Danimarca 4
SG - Singapore 4
UZ - Uzbekistan 4
A2 - ???statistics.table.value.countryCode.A2??? 3
BR - Brasile 3
CL - Cile 3
CZ - Repubblica Ceca 3
IL - Israele 3
IQ - Iraq 3
AL - Albania 2
AR - Argentina 2
EU - Europa 2
ID - Indonesia 2
JP - Giappone 2
MK - Macedonia 2
NZ - Nuova Zelanda 2
PE - Perù 2
TH - Thailandia 2
VN - Vietnam 2
ZA - Sudafrica 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BS - Bahamas 1
EC - Ecuador 1
HR - Croazia 1
LT - Lituania 1
PH - Filippine 1
PK - Pakistan 1
RS - Serbia 1
SA - Arabia Saudita 1
SV - El Salvador 1
Totale 10.906
Città #
Fairfield 1.162
Ashburn 664
Woodbridge 593
Wilmington 528
Houston 497
Seattle 458
Chandler 454
Cambridge 380
Ann Arbor 334
Dublin 240
Medford 196
Des Moines 161
Palermo 140
Jacksonville 138
Nanjing 132
Princeton 125
Dearborn 83
Altamura 80
San Diego 69
Boardman 66
Beijing 63
Lawrence 55
Changsha 53
Jinan 52
Nanchang 51
Tulsa 50
Hebei 45
New York 45
Jiaxing 40
Milan 40
Tianjin 40
Izmir 39
Seongnam 37
Shenyang 35
Ludwigshafen am Rhein 30
Ningbo 30
Rome 30
Brussels 29
Phoenix 29
Falls Church 28
London 26
Redwood City 25
Zhengzhou 25
Saint Petersburg 22
Atlanta 20
Guangzhou 17
Kumar 17
Bucheon-si 14
Frankfurt 14
Auburn Hills 13
Hangzhou 13
San Paolo di Civitate 13
Taizhou 13
Chicago 12
Florence 11
Taiyuan 11
Haikou 10
Los Angeles 10
Napoli 10
Norwalk 10
Orange 10
Verona 10
Venice 9
Bari 8
Fuzhou 8
Helsinki 8
West Jordan 8
Dallas 7
Den Haag 6
Hefei 6
Polska 6
Riposto 6
Vienna 6
Cagliari 5
Caserta 5
Düsseldorf 5
Edinburgh 5
Frankfurt am Main 5
Kilburn 5
Kunming 5
Lanzhou 5
Pisa 5
Pune 5
Redmond 5
Sheffield 5
Taipei 5
Amsterdam 4
Bologna 4
Catania 4
Cutrofiano 4
Durham 4
Foggia 4
Mexico 4
Mumbai 4
Nuremberg 4
Padova 4
Palma De Mallorca 4
Singapore 4
Taranto 4
Torino 4
Totale 7.846
Nome #
The Daily Consumption of Cola Can Determine Hypocalcemia: A Case Report of Postsurgical Hypoparathyroidism-Related Hypocalcemia Refractory to Supplemental Therapy with High Doses of Oral Calcium 320
Valutazione dell’insulino-sensibilità tramite clamp euglicemico iperinsulinemico in bambini in terapia sostitutiva con GH. 263
Predictors of microvascular complications in type 1 diabetic patients at onset: The role of metabolic memory 214
The degree of urinary hypercortisolism is not correlated with the severity of cushing’s syndrome 169
Early Lung Function Abnormalities in Acromegaly. 167
Dual-release hydrocortisone vs conventional glucocorticoids in adrenal insufficiency 163
Hepatic steatosis index in acromegaly: Correlation with insulin resistance regardless of the disease control 161
Metabolic parameters and adipokine profile during GH replacement therapy in children with GH deficiency 159
GHD come predittore di sindrome metabolica 159
Clinical and metabolic effects of first-line treatment with somatostatin analogues or surgery in acromegaly: a retrospective and comparative study 154
OCT is not useful for detection of minimal diabetic retinopathy in type 1 diabetes. 154
Alteration of the growth hormone axis, visceral fat dysfunction, and early cardiometabolic risk in adults: the role of the visceral adiposity index 154
Is diabetes in Cushing's syndrome only a consequence of hypercortisolism? 153
Visceral Adiposity Index Is Associated with Insulin Sensitivity and Adipocytokine Levels in Newly Diagnosed Acromegalic Patients. 153
Identification of Novel Wsf1 Mutations in a Sicilian Child with Wolfram Syndrome 153
Insulin resistance and hyperandrogenism drive steatosis and fibrosis risk in young females with PCOS 153
Comparison between euglycemic hyperinsulinemic clamp and surrogate indices of insulin sensitivity in children with growth hormone deficiency 151
Correlation between adrenal function, growth hormone secretion, and insulin sensitivity in children with idiopathic growth hormone deficiency 149
Janus kinase (JAK) 2 V617F mutation as the cause of primary thrombocythemia in acromegaly with severe visceromegaly and divergence between growth hormone and insulin-like growth factor-1 concentrations during the follow-up: causal or casual association? 146
The Metabolic Profile in Active Acromegaly is Gender-Specific. 145
Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels. 145
Complete biochemical control and pituitary adenoma disappearance in a child with gigantism: efficacy of octreotide therapy 136
Liraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A Real-life 48-Month Retrospective Study. 135
Resistin, visfatin, leptin and omentin are differently related to hormonal and metabolic parameters in growth hormone-deficient children 134
The visceral adiposity index is associated with insulin sensitivity and IGF-I levels in adults with growth hormone deficiency 134
Corneal thickness in children with growth hormone deficiency: The effect of GH treatment. 132
Circulating Irisin Levels in Children with GH Deficiency before and after 1 Year of GH Treatment 131
Hyperinsulinism and polycystic ovary syndrome (PCOS): role of insulin clearance. 128
Correlation between Severity of Growth Hormone Deficiency and Thyroid Metabolism and Effects of Long-Term Growth Hormone Treatment on Thyroid Function in Children with Idiopathic Growth Hormone Deficiency. 127
Improved insulin sensitivity and secretion in prediabetic patients with adrenal insufficiency on dual-release hydrocortisone treatment: a 36-month retrospective analysis 126
Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report 125
Growth hormone and hematopoiesis: A retrospective analysis on a large cohort of children with growth hormone deficiency 125
Vitamin D across growth hormone (GH) disorders: From GH deficiency to GH excess 123
Relative Hypoleptinemia in poor controlled patients with Type 1 Diabetes 121
Utility of C-peptide for a reliable estimate of insulin secretion in children with growth hormone deficiency. 120
No phenotypic differences for polycystic ovary syndrome (PCOS) between women with and without type 1 diabetes mellitus. 119
Il c-peptide come marker principale nella storia naturale del Diabete tipo 1: ruolo della funzione b-cellulare pancreatica nelle complicanze 116
The metabolic outcomes of growth hormone treatment in children are gender specific 116
Higher cardiometabolic risk in idiopathic versus autoimmune type 1 diabetes: A retrospective analysis 115
Diabetes Secondary to Acromegaly: Physiopathology, Clinical Features and Effects of Treatment. 114
Revaluation of the clinical and metabolic behavior of children with isolated growth hormone deficiency during GH treatment according to newly proposed note 39 of the Italian Medicines Agency (AIFA). 111
Insulin sensitivity and secretion and adipokine profile in patients with Cushing’s disease treated with pasireotide 111
Erratum to: Liraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A Real-life 48-Month Retrospective Study (Diabetes Therapy, (2018), 9, 1, (363-371), 10.1007/s13300-017-0338-4) 110
Prevalence and clinical features of polycystic ovarian syndrome in adolescents with previous childhood growth hormone deficiency. 108
Pasireotide versus pituitary surgery: a retrospective analysis of 12 months of treatment in patients with Cushing's disease 108
Systolic flow peak of inferior thyroid arteries in Graves’disease: A predictive parameter for the ophalmopathy development. 106
Reduction in insulin sensitivity and inadequate β-cell capacity to counteract the increase in insulin resistance in children with idiopathic growth hormone deficiency during 12 months of growth hormone treatment 106
Serum visfatin levels in acromegaly: Correlation with disease activity and metabolic alterations 106
Pasireotide treatment reduces cardiometabolic risk in Cushing’s disease patients: an Italian, multicenter study 106
Visceral adiposity index is associated with insulin sensitivity and adipocytokine levels in newly diagnosed acromegalic patients. 105
L’insulino-resistenza è il principale fattore indipendente correlato con l’aumentato rischio metabolico nelle donne affette da PCOS 105
Cornea in acromegalic patients as a possible target of growth hormone action. 103
Clamp euglicemico iperinsulinemico e test al glucagone come utili strumenti di valutazione degli effetti metabolici della terapia sostitutiva con GH. 101
Diabete e complicanze materno-fetali in gravidanza: confronto tra pazienti con diabete tipo 1 e tipo 2 pregravidico. 100
Commento a "Resistin, visfatin, leptin and omentin are differently related to hormonal and metabolic parameters in growth hormone-deficient children " 99
Commento a "The impact of real practice inappropriateness and devices' inefficiency to variability in growth hormone consumption" 98
Lacrimal glands herniation in patients with Graves’ Ophthalmopathy: an effective MRI-derived marker of disease activity 97
EFFECTS OF PASIREOTIDE TREATMENT ON CARDIOMETABOLIC RISK IN PATIENTS WITH CUSHING’S DISEASE : AN ITALIAN, MULTICENTER STUDY 93
Difficoltà di identificazione della sindrome MEN2B ad esordio infantile: iter diagnostico. 91
GH-suppression test in acromegaly: comparison between OGTT and chocolate test 89
Lacrimal gland herniation in Graves ophthalmopathy: a simple and useful MRI biomarker of disease activity 89
null 87
Improved cardiovascular and cardiometabolic risk in patients with type 1 diabetes and autoimmune polyglandular syndrome switched from glargine to degludec due to hypoglycaemic variability 85
No effect of GH/IGF-1 excess on adrenal glands in acromegalic patients 84
Rivalutazione delle caratteristiche cliniche e metaboliche di bambini con deficit isolato di ormone della crescita durante il trattamento con GH secondo la modifica alla nota 39 AIFA 84
Leptina e adiponectina nella valutazione del compenso glicometabolico in corso di diabete mellito di tipo 1 normopeso. 83
Changes in lipid profile and adipokine levels in GH deficient children during GH replacement therapy. 82
Effects of pasireotide treatment on coagulative profile: a prospective study in patients with Cushing’s disease 80
Glucose metabolism in children with growth hormone deficiency 79
Glycometabolic control in Acromegalic patients with Diabetes: a study of the effects of different treatments for GH excess and for hyperglycaemia. 78
High prevalence of hypovitaminosis D in Sicilian children affected by growth hormone deficiency and its improvement after 12 months of replacement treatment. 76
Adrenal incidentaloma: a new contributing factor in metabolic syndrome 75
Iter diagnostico "rapido" per un caso di MEN IIb in un giovane adolescente 75
Studio randomizzato controllato, della durata di 2 anni, sugli effetti e la sicurezza di differenti dosaggi di r-hGH, titolati sulla base dei livelli di IGF1 in pazienti con bassa statura in trattamento: considerazioni terapeutiche e farmacoeconomiche 75
IPOVITAMINOSI D ED EFFETTI BENEFICI DELLA TERAPIA SOSTITUTIVA CON GH SUI LIVELLI DI VITAMINA D IN BAMBINI AFFETTI DA DEFICIT DI GH 72
Alterazioni del metabolismo glucidico determinate da eccesso di ormoni controregolatori: ruolo del GH 69
Visceral Adipose function, insulin sensitivity and secretion in active acromegaly. 68
The adipose visceral dysfunction plays an important role in diabetes in Cushing disease. 68
The lacrimal gland herniation role in the Graves’ orbitopathy 67
More favorable metabolic impact of three-times-weekly versus daily growth hormone (GH) treatment in naïve GH-deficient children 65
Adrenal incidentaloma: a new contributing factor in metabolic syndrome? 63
Maggiore rischio cardiometabolico in pazienti di razza non caucasica affetti da diabete mellito di tipo 1 idiopatico rispetto alla forma autoimmune in pazienti caucasici. 63
Alterazioni del metabolismo glucidico determinate da eccesso di ormoni contro regolatori. 62
Il c-peptide come marker principale nella storia naturale del Diabete di tipo 1: ruolo della funzione b-cellulare pancreatica nelle complicanze. 62
La valutazione retinica mediante Tomografia a Coerenza Ottica (OCT) nel diabete mellito tipo 1. 60
INSULIN SECRETION AND SENSITIVITY DURING PASIREOTIDE TREATMENT IN PATIENTS WITH RECURRENT CUSHING DISEASE: A CASE SERIES 60
No effect of GH/IGF-1 excess on adrenal gland in Acromegalic patients. 57
Alte dosi di cabergolina migliorano i parametri metabolici in pazienti affetti da prolattinoma. 57
Decreased regulatory CD4+CD25+ Treg cells in newly diagnosed type 1 diabetes 57
Miglioramento clinico e metabolico in pazienti affetti da diabete mellito tipo 1 associato ad altre endocrinopatie (APS) dopo shift della terapia insulinica basale con glargine a degludec 57
One-hour post-load plasma glucose level is associated with a worse metabolic profile in children with GH deficiency 57
Alta prevalenza di Sindrome dell’ovaio policistico in donne diabetiche di tipo 1 in età fertile. 56
Increased central corneal thickness in acromegalic patients. 56
La transizione del soggetto cronicamente malato dall’età pediatrica all’età adulta 56
GH-treatment improves growth and reduces the severity of fibrosis and hypertansaminasemia in a prepubertal child with sclerosant cholangiopathy 55
Effect of the switch from conventional to “dual release hydrocortisone” in adult patients with primary and secondary adrenal insufficiency: a six-months multicenter study 55
Circulating adipokine levels in diabetic patients with Cushing disease on pasireotide treatment compared with patients with type 2 diabetes mellitus 55
Janus kinase (JAK) 2 V617F mutation as the cause of primary thrombocythemia, severe visceromegaly and divergence between growth hormone and insulin-like growth factor-1 concentrations in acromegaly due to a therapeutically resistant pituitary GH-secreting macroadenoma 53
Maggior rischio cardiometabolico nelle donne affette da Cushing, anche in assenza di una franca Sindrome Metabolica. 52
The relationship between metabolic syndrome and bone health: results of a retrospective gender specific female study. 50
Totale 10.699
Categoria #
all - tutte 36.544
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.544


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019660 0 0 0 0 0 0 0 0 0 102 273 285
2019/20203.505 383 153 246 594 360 412 282 223 288 154 322 88
2020/20211.470 112 84 146 105 102 88 141 112 180 98 124 178
2021/20221.382 51 250 49 62 70 70 41 80 143 190 81 295
2022/20231.537 183 229 24 160 172 250 132 103 163 13 78 30
2023/2024651 23 119 45 68 76 138 81 60 9 32 0 0
Totale 11.705